mmmmmm. The appendix prooves it was not speculation. It was missing, and they needed to address that lack. Nothing has changed, however, they have moved their priority from what was once their flag ship trial. And there is nothing wrong with that as the data determines what comes first as a priority. Could not say it any clearer than the appendix ann.
"We have been asked if the Company has dropped the CEP program from our list of clinical studies as it wasn’t mentioned in the latest Appendix 4C. The answer is, no, we haven’t. But it is not a priority. "
CEP is not a priority.
mmmmmm. The appendix prooves it was not speculation. It was...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 10.0¢ | $6.181K | 58.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 42445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
